Nitasha Sarswat, MD, is a board certified cardiologist that specializes in advanced heart failure and heart transplantation. Dr. Sarswat has a particular expertise in cardiac amyloidosis, pulmonary hypertension and cardiac resynchronization therapy.
Along with her clinical pursuits, Dr. Sarswat also researches a variety of cardiology topics, investigating ways to improve the treatment and management of heart failure. She has been published in several peer-reviewed journals, including Echocardiography, American Journal of Medicine and Hospital Practice.
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J. 2025 10 22; 46(40):4090-4101.
PMID: 40631729
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis.
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
PMID: 40474003
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
PMID: 40398971
Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study.
Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study. J Card Fail. 2026 Jan; 32(1):46-57.
PMID: 39954845
Early and Late Outcomes of Ambulatory Counter Pulsation Devices as a Bridge to Heart Transplantation.
Early and Late Outcomes of Ambulatory Counter Pulsation Devices as a Bridge to Heart Transplantation. Cardiology. 2025; 150(4):381-388.
PMID: 40293434
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
PMID: 39556242
Clinical and Echocardiographic Features of Individuals With Cardiac Amyloidosis at Risk for Future Thrombus Formation.
Clinical and Echocardiographic Features of Individuals With Cardiac Amyloidosis at Risk for Future Thrombus Formation. J Am Soc Echocardiogr. 2025 Feb; 38(2):135-137.
PMID: 39481665
Dynamic assessment of left ventricular coupling and myocardial reserve in patients with cardiogenic shock.
Dynamic assessment of left ventricular coupling and myocardial reserve in patients with cardiogenic shock. Eur Heart J Open. 2024 Sep; 4(5):oeae072.
PMID: 39328214
Perivascular Amyloid Deposition in Immunoglobulin Light Chain Cardiac Amyloidosis and Its Implications on Echocardiographic Cardiac Remodeling.
Perivascular Amyloid Deposition in Immunoglobulin Light Chain Cardiac Amyloidosis and Its Implications on Echocardiographic Cardiac Remodeling. J Am Soc Echocardiogr. 2024 Oct; 37(10):1010-1012.
PMID: 38960211
Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype.
Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Curr Probl Cardiol. 2024 Sep; 49(9):102729.
PMID: 38945183